论文部分内容阅读
多发性骨髓瘤(multiple myeloma,MM)患者在常规治疗达完全缓解后,体内仍会存在微小残留病变(minimal residual disease,MRD),而成为复发的根源,此时依靠机体有效的抗肿瘤免疫反应是消除MRD的一个有效的方法。树突状细胞(dendritic cell,DC)是目前功能最强大、唯一能激活初始型T细胞的抗原递呈细胞(antigen presenting cell,APC),能有效的把MM的肿瘤抗原呈递给T细胞,产生特异性CTL而达到杀灭肿瘤细胞的目的。对DC在MM免疫治疗中的基础研究和临床应用进展的研究很有意义。
In patients with multiple myeloma (MM), minimal residual disease (MRD) still exists in patients with complete remission after conventional treatment, which is the root cause of recurrence. At this time, the effective anti-tumor immune response Is an effective way to eliminate MRD. Dendritic cells (DCs) are currently the most powerful and unique antigen presenting cells (APC) that can activate naive T cells and can effectively present MM tumor antigens to T cells. Produce specific CTL to achieve the purpose of killing tumor cells. Research on the basic research and clinical application of DC in MM immunotherapy is of great significance.